Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Matson Inc (MATX) vs Medpace Holdings Inc (MEDP) Price & Performance

Matson IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Matson Inc vs Medpace Holdings Inc — how do they compare? Matson Inc trades at $214.74 (market cap $6.11B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 2.8× Matson Inc's market cap, and Matson Inc pays a 0.74% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

MATXMEDP
Market Cap
$6.11B$16.90B
Sector
TechnologyTechnology
52-Week High
$223.55$620.59
52-Week Low
$88.05$393.42
Enterprise Value
$6.71B$16.52B
Dividend Yield
0.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Matson Inc

Matson (MATX) trades at $214.52, up 2.8% today, with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, a 13.41% net margin, and robust cash flow generation. Recent Q2 2026 results exceeded expectations with EPS of $4.27 versus $3.79 estimate, driving positive analyst sentiment.

Outlook remains positive with 27% upside to consensus target of $265. Key risks include shipping industry cyclicality and global trade volatility. The combination of strong earnings momentum, attractive valuation at 13.79 P/E, and institutional support supports a constructive investment case for the stock.

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Matson Inc

Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.

Read more on MATX

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP